Payment overview · 2025
General Payments
$680.68
20 reported records · 8 companies
Healthcare provider profile · identity verified
Sheena Jose, MD
Allopathic & Osteopathic Physicians|Family Medicine · COLUMBIA, MO · NPI 1710055389
Verified facts
What the public records show
CMS Open Payments records show Sheena Jose, MD received $680.68 in general payments during 2025 across 20 reported records.
AstraZeneca Pharmaceuticals LP accounted for 67.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Farxiga by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $456.66 | 67.1% | 10 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $60.26 | 8.8% | 3 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $54.36 | 8.0% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $32.10 | 4.7% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $23.93 | 3.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.21 | 2.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.12 | 2.5% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $17.04 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $680.68 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $312.14 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $278.72 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $230.94 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $60.26 | 3 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $54.36 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $32.10 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $23.93 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $19.21 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $17.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 106 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
106 | 19 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Prednisone | Prednisone | 243 | 190 |
| Levothyroxine Sodium | Levothyroxine Sodium | 240 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 210 | 100 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 196 | 164 |
| Amlodipine Besylate | Amlodipine Besylate | 168 | 39 |
| Lisinopril | Lisinopril | 164 | 39 |
| Atorvastatin Calcium | Atorvastatin Calcium | 154 | 33 |
| Gabapentin | Gabapentin | 143 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 133 | 28 |
| Montelukast Sodium | Montelukast Sodium | 133 | 23 |
| Omeprazole | Omeprazole | 133 | 31 |
| Clonazepam | Clonazepam | 128 | 18 |
| Trazodone Hcl | Trazodone Hcl | 127 | 24 |
| Famotidine | Famotidine | 116 | 26 |
| Farxiga | Dapagliflozin Propanediol | 106 | 19 |
| Sertraline Hcl | Sertraline Hcl | 103 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 100 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 96 | 12 |
| Losartan Potassium | Losartan Potassium | 93 | 19 |
| Fluconazole | Fluconazole | 89 | 35 |
| Alprazolam | Alprazolam | 86 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 85 | 13 |
| Mounjaro | Tirzepatide | 84 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 84 | 17 |
| Furosemide | Furosemide | 83 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 76 | 14 |
| Cephalexin | Cephalexin | 75 | 69 |
| Meloxicam | Meloxicam | 66 | 17 |
| Metformin Hcl | Metformin Hcl | 64 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 63 | suppressed |
| Azithromycin | Azithromycin | 58 | 49 |
| Doxycycline Hyclate | Doxycycline Hyclate | 56 | 51 |
| Bupropion Xl | Bupropion Hcl | 55 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 54 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 54 | 11 |
| Carvedilol | Carvedilol | 52 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | 11 |
| Metoprolol Succinate | Metoprolol Succinate | 52 | 13 |
| Buspirone Hcl | Buspirone Hcl | 51 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | 15 |
| Lamotrigine | Lamotrigine | 49 | suppressed |
| Simvastatin | Simvastatin | 49 | 14 |
| Potassium Chloride | Potassium Chloride | 46 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 44 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 44 | suppressed |
| Methocarbamol | Methocarbamol | 44 | 13 |
| Topiramate | Topiramate | 44 | suppressed |
| Estradiol | Estradiol | 43 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 43 | 29 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 40 | suppressed |
| Eliquis | Apixaban | 40 | suppressed |
| Ezetimibe | Ezetimibe | 40 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 40 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 39 | suppressed |
| Spironolactone | Spironolactone | 39 | suppressed |
| Allopurinol | Allopurinol | 38 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 38 | suppressed |
| Memantine Hcl | Memantine Hcl | 38 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | 11 |
| Propranolol Hcl | Propranolol Hcl | 32 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | 26 |
| Nystatin | Nystatin | 31 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Celecoxib | Celecoxib | 28 | suppressed |
| Metronidazole | Metronidazole | 28 | 14 |
| Pregabalin | Pregabalin | 28 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 28 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 24 |
| Acetazolamide | Acetazolamide | 26 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 26 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 23 | suppressed |
| Cefdinir | Cefdinir | 23 | 20 |
| Clobetasol Propionate | Clobetasol Propionate | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 11 |
| Rexulti | Brexpiprazole | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Lorazepam | Lorazepam | 22 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | 11 |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Tobramycin | Tobramycin | 18 | 15 |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Armour Thyroid | Thyroid,pork | 16 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Carisoprodol | Carisoprodol | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 14 |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $680.68 · 20 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, FARXIGA, JOURNAVX, NEXPLANON, REXULTI, TRINTELLIX, VRAYLAR | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error